Over the last 7 days, the United States market has risen 1.2%, and over the past year, it has climbed 7.7%, with earnings expected to grow by 14% annually. In light of these conditions, identifying stocks with strong financials is crucial for investors seeking growth opportunities. Penny stocks, though often overlooked due to their smaller size or newer market presence, can offer significant potential when backed by robust fundamentals and strategic positioning in the market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.39 | $358.57M | ✅ 4 ⚠️ 3 View Analysis > |
| IDenta (OTCPK:IDTA) | $0.324 | $1.31M | ✅ 2 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $2.29 | $1.39B | ✅ 3 ⚠️ 3 View Analysis > |
| Smith Micro Software (NasdaqCM:SMSI) | $1.045 | $16.42M | ✅ 4 ⚠️ 4 View Analysis > |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.35 | $9.9M | ✅ 4 ⚠️ 1 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $3.60 | $45.28M | ✅ 4 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.63 | $89.65M | ✅ 3 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.84 | $6.12M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.29 | $72.4M | ✅ 3 ⚠️ 2 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.843 | $74.37M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 767 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
DocGo (NasdaqCM:DCGO)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: DocGo Inc. offers mobile health and medical transportation services in the United States and the United Kingdom, with a market cap of $231.90 million.
Operations: The company generates revenue from two main segments: Mobile Health Services, which contributes $423.13 million, and Transportation Services, accounting for $193.43 million.
Market Cap: $231.9M
DocGo Inc. stands out in the penny stock realm with a market cap of US$231.90 million, driven by substantial revenue streams from its Mobile Health Services and Transportation Services segments. Despite a recent net loss, the company demonstrated significant earnings growth of 191.5% over the past year, surpassing industry averages. Its financial health is bolstered by cash exceeding total debt and strong coverage of interest payments by EBIT. However, potential investors should be aware that earnings are forecasted to decline significantly over the next three years, and the board's average tenure suggests limited experience.
- Click here to discover the nuances of DocGo with our detailed analytical financial health report.
- Gain insights into DocGo's outlook and expected performance with our report on the company's earnings estimates.
Tiziana Life Sciences (NasdaqCM:TLSA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Tiziana Life Sciences Ltd is a biotechnology company engaged in discovering and developing molecules for treating oncology and immunology diseases in the United States, with a market cap of $163.63 million.
Operations: Tiziana Life Sciences Ltd does not report any specific revenue segments.
Market Cap: $163.63M
Tiziana Life Sciences, with a market cap of US$163.63 million, is pre-revenue and focused on developing innovative treatments for neurodegenerative diseases like multiple sclerosis and Alzheimer's. The company recently reported a reduced net loss of US$11.86 million for 2024, down from the previous year. Tiziana's promising clinical trials for its intranasal foralumab demonstrate potential in addressing unmet medical needs by modulating immune responses without systemic immunosuppression. Despite high share price volatility and an inexperienced management team, the company's debt-free status and ongoing strategic partnerships could support its ambitious R&D initiatives.
- Get an in-depth perspective on Tiziana Life Sciences' performance by reading our balance sheet health report here.
- Understand Tiziana Life Sciences' track record by examining our performance history report.
Jianpu Technology (OTCPK:AIJT.Y)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Jianpu Technology Inc. operates an open financial technology platform under the Rong360 brand in China, with a market cap of $40.97 million.
Operations: The company generates revenue primarily from its online financial information provider segment, totaling CN¥1.01 billion.
Market Cap: $40.97M
Jianpu Technology, with a market cap of US$40.97 million, has transitioned to profitability in the past year, reporting net income of CN¥106.13 million for 2024 compared to a loss the previous year. The company's Price-to-Earnings ratio of 2.8x suggests it may be undervalued relative to the broader US market average. Despite increased debt levels over five years, Jianpu maintains strong liquidity with short-term assets exceeding both short and long-term liabilities significantly. Recent developments include a special cash dividend announcement and executive changes, highlighting ongoing strategic adjustments within its seasoned management team.
- Unlock comprehensive insights into our analysis of Jianpu Technology stock in this financial health report.
- Review our historical performance report to gain insights into Jianpu Technology's track record.
Taking Advantage
- Access the full spectrum of 767 US Penny Stocks by clicking on this link.
- Interested In Other Possibilities? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Jianpu Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com